Actively Recruiting
The Influence and Regulatory Role of Exogenous and Endogenous Oxytocin on Top-down Attention in Humans
Led by University of Electronic Science and Technology of China · Updated on 2025-09-08
250
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying how orally administered oxytocin, given as a lingual spray, affects human top-down attention through oxytocin receptors. The study explores whether these effects depend on the dose and the type of task performed. It also evaluates the role of atosiban, an oxytocin receptor antagonist, in modifying attention processes. This early-phase trial aims to understand how oxytocin influences attention, pupil size, and anxiety in healthy adult males. Participants receive different treatments in a double-blind, placebo-controlled setup. These include placebo followed by low-dose oxytocin (24IU), placebo followed by high-dose oxytocin (48IU), placebo followed by atosiban (150ug), atosiban followed by low-dose oxytocin, or placebo followed by another placebo. Treatments are administered as sprays under and on the tongue with a 15-minute interval between doses. The design includes multiple blood and saliva samples taken before and after treatments to measure oxytocin levels. During the study, participants complete questionnaires on anxiety, depression, social anxiety, and autistic traits before treatment. After dosing, they undergo eye-tracking tests measuring error rates, response times, and pupil size while performing attention tasks. Anxiety levels are reassessed after the tasks. Researchers monitor these outcomes to assess treatment effects on attention and anxiety. The entire process includes blood and saliva collection, questionnaires, behavioral tasks, and observation over about 75 minutes of active testing.
CONDITIONS
Brief Title
The Effect of Oral Oxytocin and Atosiban on Top-down Attention ( OTAtosiban )
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy male subjects without past or current psychiatric or neurological disorders
- Age between 18 and 35 years old
You will not qualify if you...
- History of or current neurological or psychiatric disorders
- Use of psychotropic medications, including nicotine
- Visual impairments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants receive placebo followed after 15 minutes by oral administration of either oxytocin (24IU or 48IU), atosiban, a combination of atosiban and oxytocin, or placebo again. During the treatment session, questionnaires and multiple blood and saliva samples are collected to assess oxytocin levels and anxiety. Participants also complete an eye-tracking task assessing top-down attention while pupil size and response latency are measured.
1 treatment visit lasting several hours
Trial Site Locations
Total: 1 location
1
School of Life science and Technology, University of Electronic Science and Technology of China
Chengdu, Sichuan, China
Actively Recruiting
Research Team
K
Keith M Kendrick, PhD
Y
Yige Wang, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
5
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here